Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University

Biohaven advances development of its extracellular target degrader platform technology (MoDEs™) for therapies across a variety of diseases including...

Related Keywords

David Spiegel ,Jennifer Porcelli ,Mike Beyer ,Spiegel Lab ,Yale University ,Biohaven Ltd ,Biohaven Therapeutics Ltd ,Prnewswire Biohaven Ltd ,Sam Brown Inc ,Professor David Spiegel At Yale University ,Exchange Commission ,Professor David Spiegel ,Biohaven Labs ,Proteolysis Targeting Chimeras ,Professor Spiegel ,Small Molecules ,Nature Chemical Biology ,Both Yale ,Private Securities Litigation Reform Act ,Financial Condition ,Biohaven Therapeutics ,